On Wednesday, Southwestern Energy Company (NYSE:SWN)’s shares declined -6.95% to $6.29. With its recent share price change, SWN market value has reached roughly $2.60 billion. Its most recent quarter balance sheet showed the company is standing at a -0.70 current ratio and possess -1.05 as debt to equity ratio. The company has a Profit Margin (ttm) of negative -65.20% and has 74.10% gross margins. The stock’s performance in 1 month is -30.08% and its volatility for the same period is 7.97%.
Southwestern Energy Company explores, develops, and produces natural gas and oil in the United States. The company operates in two segments, Exploration, Development and Production; and Midstream Services.
Performant Financial Corp (NASDAQ:PFMT)’s shares dropped -6.11% to $1.69. The last trading range of Performant Financial Corp (NASDAQ:PFMT) ranges between $1.65 and $1.83. The EPS of the company stands at $-0.13. The 52-week range shows that the stock reached higher at $6.99 while its lower range is $1.65 in the last 52-weeks. The average volume of the company is at 98,245.00 with the Outstanding Shares of 49.46 million. The market capitalization of the company is $88.94 million. The Beta of the company stands at 1.43 with the RSI (Relative Strength Index) of 24.26.
Performant Financial Corporation provides technology-enabled recovery and related analytics services in the United States. Its services assist identify and recover delinquent or defaulted assets and improper payments for government and private clients in various markets.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)‘s shares dipped -1.09% to $6.34. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is now worth about $1.21 billion. The share price has made a 2.92% gain in the past 5 days and has lost -7.71% since 2015 kicked off. Analysts are forecasting EPS growth of -0.94% for next fiscal year and 41.40% growth in the next 5 years. The stock trades with a beta of 1.68. The stock price is below by -18.24% as contrast to the average price over the last 200 days.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
